Kedar Upadhye appointed as CFO of Biocon Biologics

Bengaluru-based Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has named Kedar Upadhye as its new Chief Financial Officer (CFO). The current CFO, MB Chinappa, will transition to a strategic finance role within the Biocon Group, effective October 31, 2023.

MB Chinappa, who has been CFO since January 2020, played a crucial role in shaping business strategy and driving profitable growth. He secured over $500 million in Private Equity investment and was instrumental in the company’s $3 billion+ acquisition of Viatris’ global biosimilars business in 2022, along with establishing a strategic vaccines partnership with the Serum Institute of India.

Kedar Upadhye, with over 23 years of global leadership experience in corporate finance, strategy, accounting, and investor relations, will assume the role of CFO at Biocon Biologics. He has held key positions at reputed organizations like Cipla, Dr. Reddy’s, PepsiCo, and Thermax. Before joining Biocon Biologics, Kedar served as the Chief Financial Officer at ReNew Energy Global Plc, a NASDAQ-listed decarbonization and renewable energy company.

Kedar expressed his enthusiasm for joining Biocon Biologics at this pivotal juncture and looks forward to contributing to the company’s journey towards becoming a leading global biosimilars enterprise. He emphasized his commitment to fostering sustainable and profitable growth in the biosimilars sector.